Literature DB >> 3374026

Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone.

I Walter-Sack1, J X de Vries, A Ittensohn, M Kohlmeier, E Weber.   

Abstract

Benzbromarone is one of the main uricosuric drugs currently used. We determined plasma concentrations of benzbromarone, bromobenzarone, and benzarone and 24 hour uric acid excretion in ten healthy individuals following fasting application of two different non-micronised benzbromarone brands. In addition we explored the influence of adjusting urinary pH to near neutral values and of concomitant food intake. Benzbromarone was more rapidly absorbed from the test preparation than from the reference preparation; the extent of systemic availability did not differ significantly. Urinary pH adjustment had no clearcut effect, whereas food intake retarded drug absorption (even though not significant because of the variability of the data). Binding of benzbromarone to plasma proteins exceeded 99%. Bromobenzarone and benzarone were not detectable and are unlikely to be major metabolites of benzbromarone. Instead we found two other compounds suggestive of metabolites, one of them being monohydroxilated benzbromarone. The plasma concentrations of the parent compound in one subject exceeded those of the rest of the group, possibly indicating genetic differences in drug metabolism. The uricosuric effect was not related to benzbromarone plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3374026     DOI: 10.1007/bf01727785

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  12 in total

1.  [Effect of benzbromarone in 100mg and 50mg doses on healthy subjects].

Authors:  F Matzkies; G Berg
Journal:  Fortschr Med       Date:  1977-07-21

2.  [Diet therapy of hyperuricemia--scientific principles and practical consequences].

Authors:  W Löffler
Journal:  Verh Dtsch Ges Inn Med       Date:  1986

Review 3.  [Urolithiasis].

Authors:  W Staehler; D Völter; H Ziegler; W D Braun
Journal:  Med Welt       Date:  1974-01-04

4.  [Treatment of hyperuricemic and gouty patients with derivatives of benzofuran].

Authors:  F Delbarre; C Auscher; J L Olivier; A Rose
Journal:  Sem Hop       Date:  1967-04-08

5.  Metabolism of benzbromarone in man.

Authors:  J Broekhuysen; M Pacco; R Sion; L Demeulenaere; M Van Hee
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

6.  [Effect of benzbromaronum on the renal uric acid excretion in healthy persons].

Authors:  N Zöllner; W Dofel; W Gröbner
Journal:  Klin Wochenschr       Date:  1970-04-01

7.  [Effect of benzbromarone on serum uric acid level and uric acid excretion of patients with gout].

Authors:  N Zöllner; A Griebsch; J K Fink
Journal:  Dtsch Med Wochenschr       Date:  1970-11-27       Impact factor: 0.628

8.  Pharmacokinetics and biotransformation of benzbromarone in man.

Authors:  H Ferber; H Vergin; G Hitzenberger
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone.

Authors:  T F Yu
Journal:  J Rheumatol       Date:  1976-09       Impact factor: 4.666

Review 10.  Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-11       Impact factor: 9.546

View more
  9 in total

1.  Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and metabolite profiles.

Authors:  I Walter-Sack; J X de Vries; A Ittensohn; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Deficient benzbromarone elimination: a familial disorder?

Authors:  N Zöllner; U Gresser; I Walter-Sack
Journal:  Klin Wochenschr       Date:  1990-01-19

3.  Benzbromarone biotransformation is not related to polymorphic oxidation of sparteine.

Authors:  I Walter-Sack; M Eichelbaum; J X de Vries; E Weber
Journal:  Klin Wochenschr       Date:  1988-11-01

4.  Variation of benzbromarone elimination in man--a population study.

Authors:  I Walter-Sack; U Gresser; M Adjan; I Kamilli; A Ittensohn; J X de Vries; E Weber; N Zöllner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Benzbromarone hydroxylation in man: defective formation of the 6-hydroxybenzbromarone metabolite.

Authors:  J X de Vries; I Walter-Sack; A Ittensohn; E Weber; H Empl; U Gresser; N Zöllner
Journal:  Clin Investig       Date:  1993-11

Review 6.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

7.  Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases.

Authors:  Robert S Foti; Philippe Diaz; Dominique Douguet
Journal:  J Enzyme Inhib Med Chem       Date:  2016-07-17       Impact factor: 5.051

8.  Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4.

Authors:  A A K El-Sheikh; J J M W van den Heuvel; J B Koenderink; F G M Russel
Journal:  Br J Pharmacol       Date:  2008-08-25       Impact factor: 8.739

Review 9.  Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.

Authors:  Arrigo F G Cicero; Federica Fogacci; Masanari Kuwabara; Claudio Borghi
Journal:  Medicina (Kaunas)       Date:  2021-01-10       Impact factor: 2.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.